PHAT INVESTOR NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
11 janv. 2023 14h48 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
08 janv. 2023 18h00 HE
|
Phathom Pharmaceuticals
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data...
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
23 nov. 2022 18h07 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
08 nov. 2022 17h00 HE
|
Phathom Pharmaceuticals
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – PHAT
02 nov. 2022 14h55 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
01 nov. 2022 08h00 HE
|
Phathom Pharmaceuticals
Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15...
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
24 oct. 2022 08h00 HE
|
Phathom Pharmaceuticals
A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S.Topline data for the primary endpoint is expected in Q1 2023 with full trial...
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
26 sept. 2022 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 08h15 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
06 août 2022 13h16 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...